Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
Filed with ASX · · 2 pages · English
• Core Japanese patent granted in major HER2 positive gastric cancer market • Patent provides method of composition and method of use protection to 2036 company today announced it has received a Notice of Grant from the Japanese Patent Office for Patent Application number 2018-505505 which protects its HER-Vaxx immunotherapy, currently in development for HER2 positive gastric cancer. The patent ti
Story so far
Earlier from Imugene
- S&P DJI Announces September 2021 Quarterly Rebalance
- Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
- Appendix 4E and Full Year Statutory Accounts
- Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
- Response to ASX Query
Later from Imugene
- First patient dosed in Phase I clinical trial of CHECKvacc
- Investor Presentation Imugene Eureka Therapeutics
- Clinical Trial Supply Agreement with Merck KGaA and Pfizer
- S&P DJI Announces December 2021 Quarterly Rebalance
- Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene